June 26 (Reuters) - Invivyd Inc IVVD.O:
INVIVYD ANNOUNCES POSITIVE FULL PHASE 1/2 CLINICAL DATA FOR VYD2311, A NEXT GENERATION COVID-19 MONOCLONAL ANTIBODY FOR POTENTIAL USE AS A NON-VACCINE PREVENTATIVE AND FOR TREATMENT OF ACTIVE INFECTION
INVIVYD INC - VYD2311 SHOWS ATTRACTIVE SAFETY PROFILE ACROSS ALL DOSING COHORTS
INVIVYD INC - TYPE C MEETING WITH FDA SCHEDULED FOR EARLY Q3
Source text: ID:nGNX8R7BBD
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.